Royalty Pharma plc Stock News

GBOOY vs. RPRX: Which Stock Is the Better Value Option?

Royalty Pharma plc announced that it is raising its full year 2023 Adjusted Cash Receipts (non-GAAP) guidance to between $2.85 billion and $2.95 billion, up from $2.375 billion and $2.475 billion pre

GBOOY vs. RPRX: Which Stock Is the Better Value Option?

Royalty Pharma plc (NASDAQ:RPRX ) Q4 2022 Earnings Conference Call February 15, 2023 8:00 AM ET Company Participants George Grofik - Senior Vice President, Head of Investor Relations & Communications

Royalty Pharma (RPRX) delivered earnings and revenue surprises of 0% and 0.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the months of February and

Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Royalty Pharma plc is an interesting investment fund that buys pharmaceutical royalties and generates a non-correlated yield. With the depressed biotech sector valuation and increasing cost of capital

Despite inflation making it hard for the healthcare industry to manage its operating costs, there are a few positives that make this sector attractive to investors.

NEW YORK, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2022 financial results on Wednesday, February 15, 202

Royalty Pharma purchases royalties on pharmaceutical products. Diversification provides some protection for investors and the company has invested in high quality assets.

Royalty Pharma Plc RPRX, -1.42% said Monday it agreed to pay up to $1.125 billion for drug royalties owned by Ionis Pharmaceuticals Inc. IONS, +1.00% . The royalties include Ionis' interests in Biogen

NEW YORK, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 11

Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business

NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Virtual C